What Are the Risk Factors for Death in Heart Failure With Preserved Ejection Fraction? Multiple variables are associated with survival in HFPEF. Key risk factors include age, gender, body mass ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

The obese models however, developed heart failure with preserved ejection fraction (HFpEF), proving that a combination of stressors give rise to the disease and providing a good model for further ...

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients ...

Pre-clinical studies demonstrated that blocking glucagon activity can improve heart function in heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

The trial was done in adults with obesity and heart failure with preserved ejection fraction (HFpEF). The data, posted online on August 1, has not yet been published in a peer-reviewed journal.